Sana Biotechnology (NASDAQ:SANA) Hits New 12-Month Low – Here’s What Happened

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $2.27 and last traded at $2.27, with a volume of 401977 shares. The stock had previously closed at $2.48.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SANA. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Sana Biotechnology in a research note on Wednesday, November 27th.

Sana Biotechnology Price Performance

The firm has a market capitalization of $421.98 million, a P/E ratio of -1.31 and a beta of 1.33. The company has a fifty day moving average of $3.20 and a 200 day moving average of $4.76.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. On average, sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Insider Transactions at Sana Biotechnology

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This represents a 5.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 31.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. FMR LLC grew its holdings in Sana Biotechnology by 16.3% in the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after purchasing an additional 4,438,949 shares during the period. Geode Capital Management LLC grew its stake in shares of Sana Biotechnology by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock valued at $13,175,000 after buying an additional 276,055 shares during the period. State Street Corp increased its position in Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after buying an additional 269,274 shares in the last quarter. Integral Health Asset Management LLC raised its stake in Sana Biotechnology by 22.4% during the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after buying an additional 220,000 shares during the period. Finally, Barclays PLC boosted its holdings in Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after acquiring an additional 178,179 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.